
Critical Advances in Systemic Therapy for HCC: Building on Recent Progress for Community Practices

Polling Overview

Produced by Your Conference Live Platform

December 10, 2020, 3:48 PM ET

: If you are a practicing clinician, how many patients with HCC do you provide care for in a typical month?

Option	Votes	Percentage
--------	-------	------------

Total 0

: Which of the following best describes your role on the oncology care team?

Option

Votes

Percentage

Total 0

: Which of the following best describes your specialty?

Option	Votes	Percentage
--------	-------	------------

Total 0

: Which of the following treatments would you consider to be the optimal choice for this patient?

Option

Votes

Percentage

Total 0

: Which of the following treatments WOULD you consider to be the optimal choice for this patient?

Option

Votes

Percentage

Total 0

: In your current practice, which of the following do you prefer as initial systemic therapy for patients with advanced HCC and Child-Pugh B liver function?

Option	Votes	Percentage
--------	-------	------------

Total 0

: In your current practice, which of the following treatments would you consider to be the optimal choice for this patient?

Option

Votes

Percentage

Total 0

: Based on the preceding discussion, which of the following treatments would you consider to be the optimal choice for this patient?

Option

Votes

Percentage

Total 0

: In general, the patient's risk of immune-related AEs would decrease after 4 months of therapy for each of the following AEs EXCEPT which one?

Option	Votes	Percentage
--------	-------	------------

Total 0

: In general, the patient's risk of immune-related AEs would decrease after 4 months of therapy for each of the following AEs EXCEPT which one?

Option	Votes	Percentage
--------	-------	------------

Total 0

: Each of the following treatments could be considered for this patient, EXCEPT which one?


Option

Votes

Percentage

Total 0

: Each of the following treatments could be considered for this patient, EXCEPT which one?



Option	Votes	Percentage
Cabozantinib	0	0.0%
Lenvatinib	1	4.0%
Nivolumab + ipilimumab	6	24.0%
Ramucirumab	12	48.0%
Sorafenib	4	16.0%
Uncertain		
Total 25		8.0%